In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.


The free consultation period for this content is over.

It is now only available year-round to HFA Silver & Gold Members, Fellows of the ESC and Young combined Members

Heart failure control in patient with coronary artery disease

Session Poster Session 4

Speaker Svetlana Liliana Mosteoru

Congress : Heart Failure 2019

  • Topic : coronary artery disease, acute coronary syndromes, acute cardiac care
  • Sub-topic : Coronary Artery Disease: Treatment, Revascularization
  • Session type : Poster Session
  • FP Number : P2136

Authors : SL Mosteoru (Timisoara,RO), R Pleava (Timisoara,RO), C Totorean (Timisoara,RO), A Dumitrescu (Timisoara,RO), L Gaita (Timisoara,RO), D Gaita (Timisoara,RO)

Authors:
SL Mosteoru1 , R Pleava1 , C Totorean1 , A Dumitrescu1 , L Gaita2 , D Gaita1 , 1University of Medicine Victor Babes, Cardiology - Timisoara - Romania , 2University of Medicine Victor Babes, Diabetes, Nutrition and Metabolic disorders Department - Timisoara - Romania ,

Citation:

Introduction: Coronary artery disease (CAD) has been steadily raising in the past few years and enhanced survival fueled by better medication and revascularization techniques has placed it as one of the primary risk factors for developing heart failure (HF). Therefore, it is essential for patients suffering from HF to have a good adherence to their treatment.

Purpose: The aim of our study was to investigate the prevalence of HF in the CAD population as well as evaluate the compliance of patients towards guideline recommendations.

Methods: We have enrolled 194 consecutive patients who have undergone PCI or CABG for acute myocardial infarction or unstable angina or stable angina between October 2016 and June 2017. Out of this lot we have selected 160 patients who developed heart failure. We have interviewed these patients regarding their medication and lifestyle and have determined their ejection fraction (EF).

Results: Out of the population with heart failure, 76.8% had a preserved EF, while 15.6% had an intermediate EF and 7.5% a reduced EF. However just over half of the patients with intermediate EF (64%) were taking an angiotensin converting enzyme (ACE) inhibitor or an angiotensin receptor blocker (ARB). The most used medication was Ramipril (43.7%), followed by Zofenopril (31.2%), Valsartan (6.2%) and Olmesartan (6.2%). In the group with reduced EF 50% of these patients were on ACE inhibitor or ARB treatment, which included Zofenopril in 66.6% of the cases, Ramipril in 33.3% of the cases and Valsartan in 33.3% of the cases. Moreover, 59% of the entire population with heart failure were not currently taking Spironolactone.

Conclusions: We have noticed that patients at very high cardiovascular risk are poorly controlled regarding their heart failure medication which might be explained by non-adherence to treatment. Awareness should be raised among patients to ensure better compliance regarding medication adherence.



Based on your interests

Members get more

Join now
  • 1ESC Professional Members – access all resources from ESC Congress and ESC Asia with APSC & AFC
  • 2ESC Association Members (Ivory, Silver, Gold) – access your Association’s congress resources
  • 3Under 40 or in training - with a Combined Membership, access resources from all congresses
Join now

Our sponsors

ESC 365 is supported by Bayer, Boehringer Ingelheim and Lilly Alliance, Bristol-Myers Squibb and Pfizer Alliance, Novartis Pharma AG and Vifor Pharma in the form of educational grants. The sponsors were not involved in the development of this platform and had no influence on its content.

logo esc

Our mission: To reduce the burden of cardiovascular disease

Who we are